Quinolinic acid
|
Basic information |
| Metabolite name | Quinolinic acid |
 | HMDB0000232 |
 |
C03722 |
 |
1066 |
| Synonyms | QUIN; |
| No. of studies | 37 |
|
Basic information |
| Metabolite name | Quinolinic acid |
| HMDB0000232 |
|
C03722 |
|
1066 |
| Synonyms | QUIN; |
| No. of studies | 37 |
|
Relationship between Quinolinic acid and depression (count: 37) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Down |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1033 | Type1 | small intestinal bacterial overgrowth and chronic constipation group vs. control group | Urine | Human | Up |
| Study M1033 | Type1 | small intestinal bacterial overgrowth and chronic diarrhea group vs. control group | Urine | Human | Up |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic constipation group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic diarrhea group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1034 | Type1 | small intestinal bacterial overgrowth and chronic constipation group vs. control group | Urine | Human | Up |
| Study M1034 | Type1 | small intestinal bacterial overgrowth and chronic diarrhea group vs. control group | Urine | Human | Up |
| Study M1035 | Type2 | mood disorder group, after tryptophan-rich diet vs. baseline | Urine | Human | Down |
| Study M1036 | Type1 | IBS-D group vs. control group | Urine | Human | Up |
| Study M1036 | Type2 | IBS-D with low-tryptophan and FODMAP diet subgroup, after diet intervention vs. baseline | Urine | Human | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1107 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type1 | CRS + FMT of adolescent depression group vs. CRS + FMT of healthy controls group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M1108 | Type1 | CRS group vs. control group | Colon | C57/6 J mouse | Up |
| Study M1108 | Type1 | CRS group vs. control group | Prefrontal cortex | C57/6 J mouse | Up |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Colon | C57/6 J mouse | Down |
| Study M1108 | Type2 | CRS + Roseburia Intestinalis. group vs. CRS group | Prefrontal cortex | C57/6 J mouse | Down |
| Study M126 | Type1 | LPS group vs. control group | Brain | CD-1 mouse | Up |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M150 | Type1 | IFN-alpha group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M150 | Type2 | IFN-alpha + imipramine group vs. IFN-alpha group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M151 | Type1 | Male FSL group vs. Male FRL group | Plasma | Sprague-Dawley rat | Down |
| Study M151 | Type1 | Female FSL group vs. Female FRL group | Plasma | Sprague-Dawley rat | Down |
| Study M159 | Type1 | depressed group vs. control group | Cerebrospinal fluid | Human | Up |
| Study M175 | Type2 | ECT treatment depressed group post-treatment vs. baseline | Plasma | Human | Down |
| Study M184 | Type1 | depressed group vs. control group | Ventrolateral prefrontal cortex | Human | Down |
| Study M450 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M450 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M470 | Type1 | rMDD group vs. control group | Plasma | Human | Up |
| Study M518 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M524 | Type1 | hydrocortisone group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M524 | Type2 | hydrocortisone + Tiansi Liquid group vs. hydrocortisone group | Plasma | Sprague-Dawley rat | Down |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M550 | Type2 | CUMS + GTD group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M596 | Type1 | elderly depression group vs. elderly control group | Urine | Human | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M684 | Type1 | LPS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M684 | Type2 | LPS + electroacupuncture group vs. LPS group | Hippocampus | Wistar rat | Down |
| Study M699 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M865 | Type1 | HIV with depression group vs. HIV without depression group | Plasma | Human | Up |
| Study M876 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Up |
| Study M897 | Type2 | behavioral activation therapy, post-therapy vs. pre-therapy | Serum | Human | Down |
| Study M976 | Type1 | small intestinal bacterial overgrowth group vs. control group | Urine | Human | Up |
| Study M976 | Type2 | small intestinal bacterial overgrowth group, after rifaximin treatment vs. baseline | Urine | Human | Down |